PMID- 27636730
OWN - NLM
STAT- MEDLINE
DCOM- 20170707
LR  - 20210929
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 13
IP  - 1
DP  - 2017 Jan
TI  - PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.
PG  - 36-49
LID - 10.1038/nrendo.2016.135 [doi]
AB  - Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic 
      complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty 
      liver disease (NAFLD), which are all related to inappropriate ectopic lipid 
      deposition. Identification of the pathogenic molecular mechanisms and effective 
      therapeutic approaches are highly needed. The peroxisome proliferator-activated 
      receptors (PPARs) modulate several biological processes that are perturbed in 
      obesity, including inflammation, lipid and glucose metabolism and overall energy 
      homeostasis. Here, we review how PPARs regulate the functions of adipose tissues, 
      such as adipogenesis, lipid storage and adaptive thermogenesis, under healthy and 
      pathological conditions. We also discuss the clinical use and mechanism of PPAR 
      agonists in the treatment of obesity comorbidities such as dyslipidaemia, T2DM 
      and NAFLD. First generation PPAR agonists, primarily those acting on PPARgamma, are 
      associated with adverse effects that outweigh their clinical benefits, which led 
      to the discontinuation of their development. An improved understanding of the 
      physiological roles of PPARs might, therefore, enable the development of safe, 
      new PPAR agonists with improved therapeutic potential.
FAU - Gross, Barbara
AU  - Gross B
AD  - Universite de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 
      F-59000 Lille, France.
FAU - Pawlak, Michal
AU  - Pawlak M
AD  - International Institute of Molecular and Cell Biology, 4 Ks. Trojdena Street, 
      02-109 Warsaw, Poland.
FAU - Lefebvre, Philippe
AU  - Lefebvre P
AD  - Universite de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 
      F-59000 Lille, France.
FAU - Staels, Bart
AU  - Staels B
AD  - Universite de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 
      F-59000 Lille, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160916
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*metabolism/pathology/therapy
MH  - Dyslipidemias/*metabolism/pathology/therapy
MH  - Humans
MH  - Non-alcoholic Fatty Liver Disease/*metabolism/pathology/therapy
MH  - Peroxisome Proliferator-Activated Receptors/*metabolism/therapeutic use
EDAT- 2016/11/04 06:00
MHDA- 2017/07/08 06:00
CRDT- 2016/09/17 06:00
PHST- 2016/11/04 06:00 [pubmed]
PHST- 2017/07/08 06:00 [medline]
PHST- 2016/09/17 06:00 [entrez]
AID - nrendo.2016.135 [pii]
AID - 10.1038/nrendo.2016.135 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2017 Jan;13(1):36-49. doi: 10.1038/nrendo.2016.135. Epub 2016 
      Sep 16.